Drugs / VLA84
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02316470 Comparator | Dec 2014 → May 2015 | Clostridium difficile colitis | Valneva Austria GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLA84 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02316470 ↗ |
| Modality | Protein / enzyme biologic | “a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B” NCT02316470 ↗ |
| Route | Intramuscular | “as i.m. (intramuscular) vaccinations into alternating arms” NCT02316470 ↗ |